Our approach builds on the compelling and growing body of evidence linking RMPs to cancer pathobiology.
Science
Pioneering a new class of small molecule precision cancer therapies that target RNA-modifying proteins and strategic adjacencies
Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Pipeline
Our high-impact portfolio contains programs across multiple oncology targets to address significant unmet needs
Accent has systematically mapped the RMP space to fuel a pipeline of transformative precision small molecule candidates.


About DHX9
Accent’s lead program is a first-in-class DHX9 inhibitor with the potential to address high unmet need indications that lack targeted therapies, including high microsatellite instable (MSI-H) cancers. This program is advancing rapidly, with a drug candidate nomination expected in the second half of 2023. DHX9 is an RNA helicase that has been reported to play important roles in replication, transcription, translation, RNA splicing, RNA processing, and maintenance of genomic stability. Overexpression of DHX9 is observed in multiple cancer types making this helicase a compelling novel oncology target.
About ADAR1
Accent is developing ADAR1 targeted therapies to address many solid tumor indications with significant unmet need as monotherapy, including non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, and head and neck squamous cell carcinomas. Data also suggests that small molecule inhibitors of ADAR1 have further potential to combine well with checkpoint inhibitors, to treat PD1 and PD-L1 relapse/refractory tumors.
In tumor cells with higher IFN signaling, small molecule inhibitors of ADAR1 induce selective cell killing and immune sensitization, making it a highly attractive target for monotherapy and in combination with immuno-oncology therapy.
Team
Dedicated experts with proven track records
Our team shares an unwavering commitment to improving health outcomes for patients with cancer and a proven track record of accomplishment. Collectively, we have contributed to more than 45 investigational new drug applications and advanced 16 FDA-approved drugs.
Stephen Blakemore, PhD
Vice President, Biological & Translational Sciences
View BioDavid Brower
Chief Business Officer
View BioAnn Boriack-Sjodin, PhD
Senior Vice President, Molecular Discovery
View BioRobert Copeland, PhD
President, Founder, Chief Scientific Officer
View BioKenneth Duncan, PhD
Vice President, Chemistry
View BioSteve Mennen
Vice President, Pre-Clinical Development
View BioShakti Narayan, PhD, JD
Chief Executive Officer
View BioSerena Silver, PhD
Vice President, Biology
View BioJacqueline Wheeler
Senior Manager, Operations & Administration
View Bio
News
The latest Accent news and presentations
4.16.23
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
4.16.23
Accent Presents: "Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer" (AACR 2023)

Join Us
Join us in our mission to develop life-changing therapies for patients
We are looking for driven, creative individuals to accentuate our team. Learn more about our values and the benefits of a career at Accent Therapeutics! For more information or to apply, please contact HR@accenttx.com.

Contact
For more information:
For general inquiries:
contactus@accenttx.comFor general inquiries:
collaborations@accenttx.com
contactus@accenttx.comFor general inquiries:
collaborations@accenttx.com